DKK420.30
2.62% day before yesterday
Copenhagen, Apr 11, 04:59 pm CET
ISIN
DK0062498333
Symbol
NOVO B
Sector
Industry

Novo Nordisk Stock price

DKK420.30
-110.20 20.77% 1M
-400.20 48.78% 6M
-203.90 32.67% YTD
-449.00 51.65% 1Y
+7.30 1.77% 3Y
+217.08 106.82% 5Y
+225.45 115.70% 10Y
Copenhagen, Closing price Fri, Apr 11 2025
+10.75 2.62%
ISIN
DK0062498333
Symbol
NOVO B
Sector
Industry

Key metrics

Market capitalization DKK1.87t
Enterprise Value DKK1.94t
P/E (TTM) P/E ratio 18.53
EV/FCF (TTM) EV/FCF 26.32
EV/Sales (TTM) EV/Sales 6.69
P/S ratio (TTM) P/S ratio 6.42
P/B ratio (TTM) P/B ratio 13.01
Dividend yield 2.71%
Last dividend (FY24) DKK11.40
Revenue growth (TTM) Revenue growth 25.03%
Revenue (TTM) Revenue DKK290.40b
EBIT (operating result TTM) EBIT DKK130.44b
Free Cash Flow (TTM) Free Cash Flow DKK73.80b
Cash position DKK26.31b
EPS (TTM) EPS DKK22.68
P/E forward 15.62
P/S forward 5.34
EV/Sales forward 5.56
Show more

Is Novo Nordisk a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Novo Nordisk Stock Analysis

Unlock Scores for Free

Analyst Opinions

34 Analysts have issued a Novo Nordisk forecast:

24x Buy
71%
8x Hold
24%
2x Sell
6%

Analyst Opinions

34 Analysts have issued a Novo Nordisk forecast:

Buy
71%
Hold
24%
Sell
6%

Financial data from Novo Nordisk

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
290,403 290,403
25% 25%
100%
- Direct Costs 44,522 44,522
24% 24%
15%
245,881 245,881
25% 25%
85%
- Selling and Administrative Expenses 48,270 48,270
8% 8%
17%
- Research and Development Expense 48,062 48,062
48% 48%
17%
149,549 149,549
34% 34%
51%
- Depreciation and Amortization 19,107 19,107
103% 103%
7%
EBIT (Operating Income) EBIT 130,442 130,442
27% 27%
45%
Net Profit 100,988 100,988
21% 21%
35%

In millions DKK.

Don't miss a Thing! We will send you all news about Novo Nordisk directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Novo Nordisk Stock News

AD HOC NEWS
20 days ago
Der dänische Pharmakonzern Novo Nordisk DK0062498333 hat sich für bis zu 2 Milliarden US-Dollar die Rechte an einem möglichen Abnehmmittel der nächsten Generation gesichert.
marktEINBLICKE
29 days ago
Während die USA mit neuen Rezessionssorgen sowie dem Zoll-Trubel zu kämpfen haben, könnte Europa aus der Not heraus für Aufbruchstimmung sorgen.
AD HOC NEWS
4 months ago
Die Aktien von Novo Nordisk DK0062498333 und Gerresheimer DE000A0LD6E6 haben sich am Montag von ihrem Kursrutsch vor dem Wochenende erholt.
More Novo Nordisk News

Company Profile

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Head office Denmark
CEO Lars Jørgensen
Employees 76,302
Founded 1931
Website www.novonordisk.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today